BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19500800)

  • 1. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
    Chu QD; Panu L; Holm NT; Li BD; Johnson LW; Zhang S
    J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
    Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
    Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
    Mizell J; Smith M; Li BD; Ampil F; Chu QD
    Ann Surg Oncol; 2009 Oct; 16(10):2711-6. PubMed ID: 19593633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer.
    Hiller DJ; Meschonat C; Kim R; Li BD; Chu QD
    Surgery; 2011 Sep; 150(3):459-65. PubMed ID: 21878231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients.
    Parker CC; Kim RH; Li BD; Chu QD
    J Surg Oncol; 2012 Sep; 106(4):393-8. PubMed ID: 22473623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.
    Wolfort R; de Benedetti A; Nuthalapaty S; Yu H; Chu QD; Li BD
    Surgery; 2006 Aug; 140(2):161-9. PubMed ID: 16904965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.
    Holm N; Byrnes K; Johnson L; Abreo F; Sehon K; Alley J; Meschonat C; Md QC; Li BD
    Ann Surg Oncol; 2008 Nov; 15(11):3207-15. PubMed ID: 18719964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.
    Byrnes KW; DeBenedetti A; Holm NT; Luke J; Nunez J; Chu QD; Meschonat C; Abreo F; Johnson LW; Li BD
    J Am Coll Surg; 2007 May; 204(5):925-33; discussion 933-4. PubMed ID: 17481512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
    Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; IeranĂ² C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
    Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
    Kaifi JT; Yekebas EF; Schurr P; Obonyo D; Wachowiak R; Busch P; Heinecke A; Pantel K; Izbicki JR
    J Natl Cancer Inst; 2005 Dec; 97(24):1840-7. PubMed ID: 16368946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.
    Kim J; Takeuchi H; Lam ST; Turner RR; Wang HJ; Kuo C; Foshag L; Bilchik AJ; Hoon DS
    J Clin Oncol; 2005 Apr; 23(12):2744-53. PubMed ID: 15837989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC; Ampil F; Burton G; Li BD; Chu QD
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
    Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
    Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
    Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.